Nuclear medicine, a type of?imaging?that uses radioactive materials, is a useful tool to detect and also treat?prostate cancer. It is a form of?diagnostic imaging?that helps radiologists determine the stage of?cancer.
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Nuclear Medicine Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Nuclear Medicine Diagnostics. This report contains market size and forecasts of Prostate Cancer Nuclear Medicine Diagnostics in global, including the following market information:
Global Prostate Cancer Nuclear Medicine Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Prostate Cancer Nuclear Medicine Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
SPECT Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Prostate Cancer Nuclear Medicine Diagnostics include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, Jubilant Pharma, NCM-USA, Progenics Pharma, Telix Pharma and ImaginAb, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Prostate Cancer Nuclear Medicine Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, by Type, 2022 (%)
SPECT
PET
Global Prostate Cancer Nuclear Medicine Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Prostate Cancer Nuclear Medicine Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Prostate Cancer Nuclear Medicine Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Prostate Cancer Nuclear Medicine Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Prostate Cancer Nuclear Medicine Diagnostics, market overview.
Chapter 2: Global Prostate Cancer Nuclear Medicine Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Prostate Cancer Nuclear Medicine Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Prostate Cancer Nuclear Medicine Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Prostate Cancer Nuclear Medicine Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Prostate Cancer Nuclear Medicine Diagnostics Overall Market Size
2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size: 2022 VS 2029
2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market
3.2 Top Global Prostate Cancer Nuclear Medicine Diagnostics Companies Ranked by Revenue
3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Prostate Cancer Nuclear Medicine Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Prostate Cancer Nuclear Medicine Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Prostate Cancer Nuclear Medicine Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Markets, 2022 & 2029
4.1.2 SPECT
4.1.3 PET
4.2 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2024-2029
4.2.3 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2024-2029
5.2.3 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2022 & 2029
6.2 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2024-2029
6.2.3 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2029
6.3.2 US Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2029
6.4.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4.4 U.K. Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4.5 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4.6 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4.7 Nordic Countries Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.4.8 Benelux Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2029
6.5.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.5.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.5.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.5.5 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.5.6 India Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2029
6.6.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.6.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2029
6.7.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.7.3 Israel Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.7.4 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
6.7.5 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2018-2029
7 Prostate Cancer Nuclear Medicine Diagnostics Companies Profiles
7.1 Blue Earth Diagnostics
7.1.1 Blue Earth Diagnostics Company Summary
7.1.2 Blue Earth Diagnostics Business Overview
7.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Blue Earth Diagnostics Key News & Latest Developments
7.2 PETNET Solutions
7.2.1 PETNET Solutions Company Summary
7.2.2 PETNET Solutions Business Overview
7.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.2.5 PETNET Solutions Key News & Latest Developments
7.3 Cardinal Health
7.3.1 Cardinal Health Company Summary
7.3.2 Cardinal Health Business Overview
7.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Cardinal Health Key News & Latest Developments
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Company Summary
7.4.2 Lantheus Medical Imaging Business Overview
7.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Lantheus Medical Imaging Key News & Latest Developments
7.5 Jubilant Pharma
7.5.1 Jubilant Pharma Company Summary
7.5.2 Jubilant Pharma Business Overview
7.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Jubilant Pharma Key News & Latest Developments
7.6 NCM-USA
7.6.1 NCM-USA Company Summary
7.6.2 NCM-USA Business Overview
7.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.6.5 NCM-USA Key News & Latest Developments
7.7 Progenics Pharma
7.7.1 Progenics Pharma Company Summary
7.7.2 Progenics Pharma Business Overview
7.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Progenics Pharma Key News & Latest Developments
7.8 Telix Pharma
7.8.1 Telix Pharma Company Summary
7.8.2 Telix Pharma Business Overview
7.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Telix Pharma Key News & Latest Developments
7.9 ImaginAb
7.9.1 ImaginAb Company Summary
7.9.2 ImaginAb Business Overview
7.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.9.5 ImaginAb Key News & Latest Developments
7.10 Theragnostics
7.10.1 Theragnostics Company Summary
7.10.2 Theragnostics Business Overview
7.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.10.5 Theragnostics Key News & Latest Developments
7.11 Novartis
7.11.1 Novartis Company Summary
7.11.2 Novartis Business Overview
7.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.11.5 Novartis Key News & Latest Developments
7.12 Alliance Medical
7.12.1 Alliance Medical Company Summary
7.12.2 Alliance Medical Business Overview
7.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2018-2023)
7.12.5 Alliance Medical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Prostate Cancer Nuclear Medicine Diagnostics Market Opportunities & Trends in Global Market
Table 2. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers in Global Market
Table 3. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints in Global Market
Table 4. Key Players of Prostate Cancer Nuclear Medicine Diagnostics in Global Market
Table 5. Top Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Prostate Cancer Nuclear Medicine Diagnostics Product Type
Table 9. List of Global Tier 1 Prostate Cancer Nuclear Medicine Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2024-2029
Table 30. Blue Earth Diagnostics Company Summary
Table 31. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 32. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Blue Earth Diagnostics Key News & Latest Developments
Table 34. PETNET Solutions Company Summary
Table 35. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 36. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. PETNET Solutions Key News & Latest Developments
Table 38. Cardinal Health Company Summary
Table 39. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 40. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Cardinal Health Key News & Latest Developments
Table 42. Lantheus Medical Imaging Company Summary
Table 43. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 44. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Lantheus Medical Imaging Key News & Latest Developments
Table 46. Jubilant Pharma Company Summary
Table 47. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 48. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Jubilant Pharma Key News & Latest Developments
Table 50. NCM-USA Company Summary
Table 51. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 52. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. NCM-USA Key News & Latest Developments
Table 54. Progenics Pharma Company Summary
Table 55. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 56. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Progenics Pharma Key News & Latest Developments
Table 58. Telix Pharma Company Summary
Table 59. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 60. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Telix Pharma Key News & Latest Developments
Table 62. ImaginAb Company Summary
Table 63. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 64. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. ImaginAb Key News & Latest Developments
Table 66. Theragnostics Company Summary
Table 67. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 68. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. Theragnostics Key News & Latest Developments
Table 70. Novartis Company Summary
Table 71. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 72. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 73. Novartis Key News & Latest Developments
Table 74. Alliance Medical Company Summary
Table 75. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 76. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 77. Alliance Medical Key News & Latest Developments
List of Figures
Figure 1. Prostate Cancer Nuclear Medicine Diagnostics Segment by Type in 2022
Figure 2. Prostate Cancer Nuclear Medicine Diagnostics Segment by Application in 2022
Figure 3. Global Prostate Cancer Nuclear Medicine Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2022
Figure 8. By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 16. US Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 20. Germany Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 21. France Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 28. China Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 32. India Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 34. Brazil Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2018-2029
Figure 37. Turkey Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 41. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
